Helixmith Co., Ltd
084990 | KO
Overview
Corporate Details
- ISIN(s):
- KR7084990001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로7길 21, 강서구
- Website:
- https://www.helixmith.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-18 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.3 MB | ||
| 2025-07-09 00:00 |
AGM Information
임시주주총회결과
|
Korean | 6.1 KB | ||
| 2025-06-19 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 51.3 KB | ||
| 2025-06-18 00:00 |
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
|
Korean | 15.2 KB | ||
| 2025-06-18 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 48.4 KB | ||
| 2025-05-16 00:00 |
Quarterly Report
[기재정정]분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.0 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 5.7 KB | ||
| 2025-05-02 00:00 |
Legal Proceedings Report
소송등의판결ㆍ결정 (주주총회소집허가)
|
Korean | 6.2 KB | ||
| 2025-03-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.0 KB | ||
| 2025-03-27 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-03-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 10.1 KB |
Automate Your Workflow. Get a real-time feed of all Helixmith Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Helixmith Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Helixmith Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America
INSM
United States of America
INSM
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America
TIL
United States of America
TIL
Develops injected therapies to kill tumors locally and activate a systemic immune response.
United States of America
INTS
United States of America
INTS
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel
INCR
Israel
INCR
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden
IVACC
Sweden
IVACC
Develops phage therapeutics and molecular diagnostics to combat infectious diseases.
South Korea
048530
South Korea
048530
Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.
France
IVA
France
IVA
Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.
United States of America
IVA
United States of America
IVA
Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.
United States of America
IVVD
United States of America
IVVD
Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.
United States of America
IOBT
United States of America
IOBT